Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice

Inclusion Criteria: * Females aged 18 years or older at enrolment * Who have never been treated with (naïve) in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment using fresh or frozen ejaculated sperm from male partner or sperm donor * Who are prescribed REKOVELLE® for the first time, using the dosing algorithm-based on AMH test result and body weight to define the 1st cycle dose regimen with REKOVELLE® according to the approved label * Who have been informed verbally and in writing about this trial content, signed the inform consent and who do not object to their data being electronically processed Exclusion Criteria: * Currently participating in an interventional clinical trial in which any treatment or follow-up is mandated * Women with a contraindication for prescription of REKOVELLE® treatment * Hypersensitivity to the active substance or to any of the excipients * Tumours of the hypothalamus or pituitary gland * Ovarian enlargement or ovarian cyst not due to polycystic ovarian syndrome * Gynaecological haemorrhages of unknown aetiology * Ovarian, uterine, or mammary carcinoma * Primary ovarian failure * Malformations of sexual organs incompatible with pregnancy * Fibroid tumours of the uterus incompatible with pregnancy * Pregnancy and breast feeding * Women who undergo ovarian stimulation for fertility preservation * Women placed under judicial protection, guardianship, or supervision * Women who are considered as vuln…